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The AMP-activated protein kinase (AMPK) is a
master regulator of metabolic homeostasis by
sensing cellular energy status. AMPK is mainly acti-
vated via phosphorylation by LKB1 when cellular
AMP/ADP levels are increased. However, how
AMP/ADP brings about AMPK phosphorylation re-
mains unclear. Here, we show that it is AMP, but
not ADP, that drives AXIN to directly tether LKB1 to
phosphorylate AMPK. The complex formation of
AXIN-AMPK-LKB1 is greatly enhanced in glucose-
starved or AICAR-treated cells and in cell-free
systems supplementedwith exogenous AMP. Deple-
tion of AXIN abrogated starvation-induced AMPK-
LKB1 colocalization. Importantly, adenovirus-based
knockdown of AXIN in the mouse liver impaired
AMPK activation and caused exacerbated fatty liver
after starvation, underscoring an essential role of
AXIN in AMPK activation. These findings demon-
strate an initiating role of AMP and demonstrate
that AXIN directly transmits AMP binding of AMPK
to its activation by LKB1, uncovering themechanistic
route for AMP to elicit AMPK activation by LKB1.
INTRODUCTION
Levels of AMP and ADP, as a result of consuming ATP, will rise
under nutrient-poor conditions or when exercise is heightened
(Hardie et al., 2012b; Carling et al., 2012). To maintain energy
homeostasis, regulatory proteins inside the cell must possess
the ability to sense the falling energy status. The AMP-activated
protein kinase (AMPK) has been shown to be the principal
sensor, switching off anabolic pathways such as fatty acid,
triglyceride, cholesterol, and protein synthesis, and switching
on catabolic pathways such as fatty acid oxidation and glycol-
ysis. By virtue of switching off the anabolic processes, at least546 Cell Metabolism 18, 546–555, October 1, 2013 ª2013 Elsevier Inin part, AMPK activation also suppresses cell proliferation, which
may account for the tumor suppression of its upstream
activating kinase liver kinase B1 (LKB1) (Hardie and Alessi,
2013; Hardie et al., 2012a; Motoshima et al., 2006). These prop-
erties have led to growing efforts to pharmacologically target
AMPK for treating metabolic diseases including obesity, type 2
diabetes, cardiovascular diseases, and cancer (Steinberg and
Kemp, 2009).
In mammals, AMPK exists as a heterotrimer, comprised of one
catalytic subunit (a) and two regulatory subunits (b and g). The
catalytic a subunit contains an N-terminal Ser/Thr kinase
domain, followed by an autoinhibitory domain (AID) that directly
binds to and thus inhibits the kinase domain (Chen et al., 2009;
Crute et al., 1998; Pang et al., 2007). The mechanism of AMPK
activation requires the presence of LKB1 that phosphorylates
the conserved threonine residue in the activation loop of AMPKa
(Thr172 in human a1), leading to amore than 100-fold increase of
its kinase activity (Hawley et al., 1996, 2003; Shaw et al., 2004;
Woods et al., 2003). LKB1 is allosterically activated when form-
ing a heterotrimeric complex with the pseudokinase STRAD
and the adaptor protein MO25 (Baas et al., 2003; Boudeau
et al., 2003; Hawley et al., 2003; Zeqiraj et al., 2009). Genetic
depletion of LKB1 leads to aberrant activation of AMPK (Shaw
et al., 2005). AMPK can also be phosphorylated at Thr172 in
response to calcium flux, through calmodulin-dependent protein
kinase kinase b (CaMKKb) (Hawley et al., 2005; Hurley et al.,
2005; Woods et al., 2005). In addition to phosphorylation,
acetylation/deacetylation has also been suggested to take part
in the regulation of AMPK activity (Lin et al., 2012). The AMPKb
subunit plays a key role in heterotrimerization by tethering the
a subunits and g subunits (Hudson et al., 2003; Iseli et al.,
2005). Recently, myristoylation on AMPKb that facilitates
membrane binding of AMPK is reported as an essential step
for the initiation of AMPK signaling in response to rises in both
AMP and ADP (Oakhill et al., 2010, 2011).
The g subunit contains four tandem repeats (CBS1–CSB4) that
form four putative binding sites for adenosyl-containing mole-
cules (Bateman, 1997; Kemp, 2004; Scott et al., 2004), and the
binding of different nucleotides can lead to significant changes
of the g subunit conformation (Chen et al., 2012), endowingc.
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AXIN Is a Scaffold for AMPK Activation by LKB1AMPK with the ability to sense physiological AMP or ADP eleva-
tion from stresses such as nutrient deprivation, hypoxia, or pro-
longed exercises. Several functional modes of AMP and ADP
have been demonstrated: promoting Thr172 phosphorylation
at AMPKa (Hawley et al., 1995, 2003; Oakhill et al., 2010, 2011)
and preventing AMPK dephosphorylation (Davies et al., 1995;
Oakhill et al., 2010, 2011; Sanders et al., 2007). Studies have
also shown that AMP causes AMPK to undergo allosteric
changes (Chen et al., 2009; Moore et al., 1991; Oakhill et al.,
2010; Suter et al., 2006). However, although early studies
employing crude AMPK and its upstream kinase reported a
direct promoting effect of AMP on Thr172 phosphorylation
(Davies et al., 1995; Moore et al., 1991), follow-up experiments
demonstrated that recombinant AMPK expressed in E. coli
was not stimulated by AMP (Sanders et al., 2007; Suter et al.,
2006; Woods et al., 2003). Recently this discrepancy was recon-
ciled by using COS-7-cell-expressed AMPK heterotrimer con-
taining myristoylated AMPKb (Oakhill et al., 2010), highlighting
the significance of additional eukaryotic modification in AMPK
activation. It is important to note that the effects of AMP and
ADP on AMPK activation are elicited by direct binding to
AMPK, but not by regulating the upstream activating kinase
LKB1 or phosphatase (Hardie et al., 2012b). Thus, how AMP or
ADP promotes AMPK activation is mechanistically unclear.
Here, we show that AMP, but not ADP, directly triggers a
signaling loop for AMPK activation, in that AMP binding drives
AMPK to interact with AXIN-LKB1, resulting in the formation of
the AXIN-AMPK-LKB1 complex to facilitate phosphorylation of
LKB1 toward AMPK. Importantly, knockdown of AXIN renders
AMPK unable to be activated, leading to exacerbated starva-
tion-induced fatty liver as a result of dysregulated AMPK target
proteins or genes such as acyl-CoA carboxylase (ACC) and
sterol regulatory element-binding protein-1c (SREBP-1C). We
have thus uncovered a necessary role of AXIN, which integrates
the activating role of AMP, allosteric changes upon nucleotide
binding, the requirement of LKB1, and myristoylation of the b
subunit as a necessary element for AMPK activation in response
to energy stress.
RESULTS
AXIN Is Essential for AMPK Activation and Regulation
of Lipid Homeostasis
AXIN was originally discovered as a central regulator of Wnt
signaling, and its deficiency leads to duplication of body axis
(Zeng et al., 1997). It has also been shown to play critical roles
in the crosstalk between Wnt signaling and regulation of
mammalian target of rapamycin (mTOR) (Inoki et al., 2006),
cell-fate determination upon DNA damage (Li et al., 2009), and
insulin-stimulated glucose uptake (Guo et al., 2012). In the pre-
sent study, we employed adenovirus-based gene silencing
approach to specifically deplete AXIN in the mouse liver, the
organ that plays a major role in metabolism on all levels. Severe
starvation may lead to steatosis (Kneeman et al., 2012; van
Ginneken et al., 2007). Knockdown of AXIN separately by two
independent siRNAs significantly increased hepatic triglyceride
contents in both fed and 16 hr-fasted mice, as measured by a
colorimetric assay and oil red O staining (Figures 1A and 1B
and see Figure S1 [available online]). The effect of AXIN knock-Celldown was particularly marked in fasted mice, suggesting a
defect in the control of lipid biosynthesis. As AMPK plays a key
role in lipid homeostasis (Assifi et al., 2005; Steinberg and
Kemp, 2009), we first investigated the activity of AMPK by deter-
mining levels of phosphorylation of Thr172 on AMPKa, and
phosphorylation of its substrate ACC, a critical enzyme control-
ling the rate of the synthesis of fatty acids. ACC is inhibited upon
phosphorylation by AMPK (Davies et al., 1990). As shown in Fig-
ures 1C and 1D, levels of phospho-AMPK and phospho-ACC
were greatly reduced in both regularly fed (basal) and starved
mice injected with adenovirus delivering AXIN siRNA compared
to the respective mice injected with the control virus, indicating
that AMPK is not properly activated when AXIN is knocked
down. This conjecture is also supported by the observation
that the mRNA levels of SREBP-1C, a target gene negatively
regulated by AMPK (Li et al., 2011), and of fatty acid synthase
(FAS) and stearoyl-CoA desaturase-1 (SCD-1), the target genes
of SREBP-1C, were significantly increased in the mice with AXIN
knockdown (Figure 1E). These data indicate that depletion of
AXIN results in exacerbated fatty liver under prolonged starva-
tion, which could be attributed to attenuated AMPK inhibition
of lipogenesis and its upregulation of lipid consumption.
We also investigated the connection between AXIN and AMPK
in regulating lipid metabolism in cell-culture systems. Human
liver L02 cells were transfectedwithAXIN siRNA vector or control
empty vector carrying a GFP reporter. Oleic acid was kept in the
culture medium overnight to increase the basal lipid content.
Knockdown of AXIN led to a much greater increase of lipid drop-
lets compared to cells transfectedwith control vector (Figure 2A).
The culture medium was then changed to glucose-free medium
or supplementedwith the cell-permeable AMPmimetic AICAR to
speed up fat consumption. An obvious fall in the lipid content
was observed in control vector transfected cells, which was
partially blocked by depletion of AXIN (Figures 2A and S2A).
We also investigated the lipid contents in AMPKa1 and AMPKa2
double knockout (DKO) mouse embryonic fibroblasts (MEFs).
Deficiency of AMPKa led to enhanced lipid accumulation in cells
treated with oleic acid (Figures 2B and S2B). The content of lipids
failed to decrease when these cells were deprived of glucose or
treated with AICAR (Figure S2B), resembling the effect of knock-
down of AXIN (Figure S2C). AXIN siRNA made no further accu-
mulation of lipid droplets in AMPKa DKO MEFs (Figure 2B),
indicating that AXIN and AMPK function in the same axis for con-
trolling lipid homeostasis. In L02 cells, the hepatic cancer HepG2
cells, or MEF cells, knockdown of AXIN severely impaired AMPK
activation induced by glucose starvation (Figures 2C and S2D),
by treatment with 2-deoxy-D-glucose (2-DG) (Figures 2D and
S2D), or AICAR (Figures 2E and S2D–S2F). These results indi-
cate that AXIN is essential for AMPK activation in intact cells.
AXIN, AMPK, and LKB1 Form a Complex
We then explored the mechanism by which AXIN modulates
AMPK activation, first by testing whether AXIN could physically
interact with AMPK or the activating kinase LKB1 in the cells.
We subjected lysates of MEF cells to immunoprecipitation (IP)
by antibody against AMPK, followed by immunoblotting to
detect AXIN and LKB1-STRAD-MO25 as well as AMPK. AXIN
was coimmunoprecipitated with AMPK along with LKB1-
STRAD-MO25, and their coimmunoprecipitation (coIP) wasMetabolism 18, 546–555, October 1, 2013 ª2013 Elsevier Inc. 547
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Figure 1. Exacerbated Fatty Liver in Mice
Depleted of Hepatic AXIN
(A) Adenovirus expressing AXIN siRNA or control
vector was injected into the tail veins of 3-month-
old BALB/c mice. Five days later, hepatic
triglyceride (TAG) contents in the liver of the fed or
16 hr-fasted mice were determined. The dark-light
cycle is from 8 a.m. to 8 p.m. The food was with-
drawn from the cage at 5 p.m., and the mice were
sacrificed at 9 a.m. the next day. Values are pre-
sented as mean ± SEM, n = 5–7, ***p < 0.001,
yyyp < 0.001 (ANOVA followed by Tukey).
(B) Oil red O staining of sections of the livers from
control and AXIN knockdown mice in fed or fasted
state.
(C) Immunoblot analysis of phospho-AMPKa,
phospho-ACC, total levels of AMPKa, ACC, and
AXIN in the livers of the infected mice.
(D) Statistical analysis of p-AMPKa/AMPKa and p-
ACC/ACC levels in the livers of infected mice.
Values are presented as mean ± SEM, n = 8–10,
*p < 0.05, ***p < 0.001, yyyp < 0.001 (ANOVA fol-
lowed by Tukey).
(E) Levels of SREBP-1C, FAS, andSCD-1mRNA in
the liver of mice infected with AXIN siRNA-2.
Control and Adeno-siAXIN-2-infected mice were
sacrificed on day 5 after virus injection. Livers were
quickly removed and fixed in Trizol reagent. The
mRNA levels of SREBP-1C, FAS, and SCD-1were
analyzed by real-time-RT-PCR. Values are pre-
sented as mean ± SEM, n = 4, **p < 0.01, ***p <
0.001, yyyp < 0.001 (ANOVA followed by Tukey).
See also Figure S1.
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AXIN Is a Scaffold for AMPK Activation by LKB1dramatically enhanced by glucose starvation (Figure 3A, left
panel). Similarly, when IP was performed with antibody against
AXIN, increased amounts of AMPK and LKB1-STRAD-MO25
were coimmunoprecipitated under starvation (Figure 3A, right
panel; Figure S3A). Pull-down assays showed a direct interac-
tion between AXIN and LKB1 as well as between AXIN and
AMPK holoenzyme (Figures 3B and 3C). As STRAD and MO25
were coprecipitated with AXIN, we asked whether such associ-
ation depends on the presence of LKB1. In LKB1-deficient HeLa
cells transfected with HA-STRAD, FLAG-MO25, and Myc-AXIN
as indicated, no interaction between AXIN and STRAD or
MO25 was detected. LKB1 overexpression in these cells
restored the interaction between these proteins (Figure S3B).
However, knockdown of AXIN attenuated glucose starvation-
enhanced LKB1-STRAD-MO25 interaction (Figure S3C).
Domain mapping using a series of deletion mutants of AXIN
revealed that the region encompassing residues aa 507–731 is
critical for interacting with both LKB1 and AMPK (Figures S3D–
S3F), coinciding with the sites for interacting with PP2c,
RNF111, PIRH2, and TIP60 (Li et al., 2009; Liu et al., 2006; Stro-
vel et al., 2000).
To unequivocally determine whether AXIN, AMPK, and LKB1
could coexist in the same complex, we employed a two-step
coIP assay using lysates from cells coexpressing FLAG-AXIN,548 Cell Metabolism 18, 546–555, October 1, 2013 ª2013 Elsevier Inc.HA-AMPK, and Myc-LKB1, in that AXIN
was immunoprecipitated with anti-
FLAG, and the eluted proteins were sub-jected to a second round of IP by using anti-HA to precipitate
AMPK. The result showed that the three components were all
detected in the final immunoprecipitate (Figure S3G). We next
explored the possibility that AXIN might facilitate the
association of LKB1 with AMPK by ectopically expressing
AXIN in HEK293T cells. It was found that increased expression
of AXIN indeed facilitates the interaction between AMPK and
LKB1 (Figure S3H). Immunofluorescent costaining in L02 cells
revealed that knockdown of AXIN abrogates the colocalization
of AMPK and HA-LKB1 in cells deprived of glucose (Figure 3D).
It is observed that AXIN knockdown depressed the increase of
LKB1 cytosol localization upon GS treatment (Figure 3D and
Figure S3I).
We also tested for a possible role of AXIN in the CaMKK-
b-AMPK axis. Knockdown ofAXIN did not blunt AMPK activation
in LKB1-deficient HeLa cells by the CaMKKb activator calcium
ionophore A23187 (Figure S3J). Consistently, no interaction
between AXIN and CaMKKb was detected (Figure S3K). These
results indicate that AXIN specifically regulates the AMPK phos-
phorylation process catalyzed by LKB1 but not by CaMKKb.
AMP Increases the Affinity of AMPK for AXIN
We then set out to investigate how the formation of the AXIN-
AMPK-LKB1 complex is regulated. Nucleotide binding is
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Figure 2. AXIN Is Essential in AMPK Activa-
tion
(A) Knockdown AXIN promotes lipid accumulation
in L02 cells. Human liver L02 cells were trans-
fected with pLL3.7-GFP or pLL3.7-GFP-siAXIN
expressing siRNA against AXIN. Some 6 hr later,
L02 cells were incubated in medium with 200 mM
sodium oleate overnight. Then cells were washed
once with PBS and cultured in medium with or
without glucose (1 mM AICAR) for 4 hr. Lipid
droplets were stained with Nile red (0.05 mg/ml) for
10 min. GS, glucose starvation.
(B) Depletion of AMPKa exhibits similar effect on
lipid accumulation as AXIN knockdown. AMPKa1
and AMPKa2 double knockout MEFs (AMPKa
DKO) and its wild-type (WT) counterparts were
infected with Adeno-GFP-siAXIN-1 virus or
Adeno-GFP virus as a control. Six hours later, cells
were incubated in fresh medium supplemented
with 200 mM sodium oleate overnight (20 hr). Lipid
droplets were stained with Nile red (0.05 mg/ml) for
10 min.
(C–E) Impaired AMPK activation in AXIN knock-
down cells. L02 cells (C), HepG2 cells (D), or MEF
cells (E) were infected by lentivirus expressing
control siRNA or AXIN siRNA. Cells were incu-
bated with culture medium deprived of glucose for
1 hr (C) and treated with 2-DG (25 mM) (D) or
AICAR (1 mM) (E) for 30 min. Cell lysates were then
analyzed by immunoblotting with indicated anti-
bodies.
See also Figure S2.
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AXIN Is a Scaffold for AMPK Activation by LKB1reported to be essential for promoting Thr172 phosphorylation
on AMPKa (Hawley et al., 2003; Oakhill et al., 2010, 2011). We
thus tested the effect of adenosyl nucleotides on the interac-
tion of AXIN and AMPK at their endogenous levels in a cell-
free system. Addition of AMP to L02 cell lysates robustly
increased the coIP of AMPK and AXIN, whereas ATP
decreased the interaction (Figures 4A and 4B). Surprisingly,
ADP had no effect on the interaction between AXIN and
AMPK (Figure 4A). We also analyzed the AXIN-AMPK interac-
tion in cells treated with AICAR. It was found that AICAR signif-
icantly increased the affinity of AMPK for AXIN (Figure 4C). To
further test the importance of AMP binding in enhancing the
affinity of AMPK for AXIN, we expressed an AMPK holoenzyme
with the g-D317A mutation in CBS4 which is unable to bind
AMP (Adams et al., 2004; Chen et al., 2012; Xiao et al.,
2007). Exogenous AMP did not increase the affinity of the
human AMPK mutant for AXIN in the lysates of HEK293T cells
(Figure 4D).Cell Metabolism 18, 546–555AMPK Myristoylation Is Required
for AMP-Induced AXIN-AMPK
Interaction
When we tried to test the promoting ef-
fect of AMP on AXIN-AMPK interaction
by in vitro reconstitution using purified
proteins expressed in bacteria, it was
found that AMP failed to, or only mildly,
increase the affinity of AMPK for AXIN
(Figures 5A and S4A). The discrepancybetween the results obtained using bacterially purified AMPK
and eukaryotically expressed native AMPK suggested that
posttranslational modification is required for AMP to promote
AXIN-AMPK interaction. As it was reported that myristoylation
is necessary for AMP or ADP to promote AMPK activation
(Oakhill et al., 2010, 2011), we tested whether the increased
AMPK-AXIN interaction requires prior myristoylation of AMPK
b subunit in the cell by ectopically expressing AMPKb-G2A, a
mutant with its myristoylation site Gly2 changed to Ala. As
shown in Figure 5B, AMPKb-G2A blunted the AMP-enhanced
interaction between AMPK and AXIN. The effect of AMP on
the affinity of myristoylated AMPK for AXIN was recapitulated
by in vitro reconstitution, in that AMPK was purified from bac-
teria cotransformed with or without N-myristoyltransferase 1
(NMT1) (Figures 5C and S4B). Consistent with the result in
cell-free systems, AMP increased the affinity of AMPK for
AXIN, while addition of ADP has no discernible effect (Figures
5D and S4C). We also found that AMP promotes the, October 1, 2013 ª2013 Elsevier Inc. 549
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Figure 3. Complex Formation among AXIN,
AMPK, and LKB1
(A) Coimmunoprecipitation (coIP) of endogenous
AXIN, AMPK, and LKB1 in MEF cells deprived of
glucose. Protein extracts were immunoprecipi-
tated with antibody against AMPKa (left panel) or
AXIN (right panel), followed by immunoblotting
with antibodies indicated. TCL, total cell lysate.
(B) Direct interaction between AXIN and LKB1.
AXIN and LKB1were incubated in a cell lysis buffer
described in the Experimental Procedures. Pull-
down assays were performed with antibody
against LKB1 (left panel) or AXIN (right panel),
and the immunoprecipitates were subjected to
immunoblotting with indicated antibodies.
(C) Direct interaction between AXIN and AMPK
complex. Pull-down assays were performed with
antibody against AMPKa (left panel) or AXIN
(right panel), followed by immunoblotting with
antibodies indicated.
(D) Glucose deprivation-induced colocalization
between AMPK and LKB1 depends on AXIN.
Knockdown of AXIN impaired the association of
HA-LKB1 with AMPK in L02 cells glucose starved
for 3 hr. Mouse anti-AMPKa antibody, donkey anti-
mouse IgG Alexa Fluor 488 secondary antibody for
AMPKa (green), and rabbit anti-HA antibody and
donkey anti-rabbit IgG Alexa Fluor 594 secondary
antibody for LKB1 (red) were used.
See also Figure S3.
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AXIN Is a Scaffold for AMPK Activation by LKB1interaction of AMPK and AXIN in a dose-dependent manner
(Figure 5E). Such an increase was not seen with the AXIN
mutant lacking the region of aa 507–731, a domain that was
mapped responsible for binding to AMPK and LKB1 (Figure 5F).
These results indicate that myristoylation on AMPKb is a
prerequisite modification for AMP to drive AMPK to interact
with AXIN.550 Cell Metabolism 18, 546–555, October 1, 2013 ª2013 Elsevier Inc.AXIN Promotes Phosphorylation of
AMPK by LKB1
We then investigated the effects of AXIN
and AMP on the phosphorylation of
AMPK by LKB1, a crucial step for AMPK
activation. We first tested whether the
AMPK-LKB1 interaction is modulated by
AMP in the presence or absence of
AXIN using in vitro reconstitution. When
AXIN was absent, AMP failed to increase
the association of LKB1 with AMPK
regardless of myristoylation. In the pres-
ence of AXIN, AMP enhanced the
interaction of LKB1 with AMPK most
dramatically when the AMPK protein is
myristoylated (Figures 6A, S5A, and
S5B). Consistent with its inability to pro-
mote AMPK-AXIN interaction, ADP did
not enhance the interaction between
LKB1 and myristoylated AMPK even
when AXIN was present (Figure 6B). We
also analyzed the effects of AXIN andAMP on AMPK-LKB1 interaction in a cell-free system using
lysates from MEF cells. AMP addition increased the amount of
LKB1 in the AMPK immunoprecipitate from the MEF cells, but
not from AXIN siRNA-expressing cells (Figure 6C), indicating
that AMP depends on AXIN to promote AMPK-LKB1 interaction.
Similar results were obtained in AICAR-treated MEF cells (Fig-
ures 6D and S5C). These results demonstrate that the interaction
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Figure 4. AMP Increases the Affinity of AMPK for AXIN
(A) Exogenous AMP promotes interaction between AXIN and AMPK. L02 liver
cell lysates were incubated with 200 mM AMP, ADP, or ATP-g-S together with
20 mMadenylate kinase inhibitor Ap5A overnight at 4
C. IP was then performed
against AMPKa using the lysates, followed by immunoblotting using the
antibodies indicated.
(B) Exogenous AMP enhances the interaction between endogenous AMPK
and AXIN. Lysates of L02 liver cells were incubated with AMP overnight at 4C.
IP was then performed against AXIN using the lysates, followed by immuno-
blotting using the antibodies indicated.
(C) AICAR promotes AXIN-AMPK interaction. L02 liver cells were treated with
AICAR (1 mM) for 1 hr. IP was then performed against AMPKa using cell
lysates, followed by immunoblotting using the antibodies indicated.
(D) Mutational analysis for the importance of AMP binding to AMPKg in
intrasteric regulation of the affinity of AMPK for AXIN. AMPKg1 or AMPKg1-
D317A was cotransfected with Myc-AXIN, HA-AMPKa, and AMPKb into
HEK293T cells. The lysates of the transfected cells were added with or without
AMP, followed by IP using anti-Myc antibody.
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AXIN Is a Scaffold for AMPK Activation by LKB1between AMPK and LKB1 is regulated and that AXIN is essential
for AMP- or AICAR-enhanced LKB1-AMPK association.
We then explored the functional consequence of AXIN on
AMPK activation by assessing Thr172 phosphorylation on
AMPKa. AXIN and AMP synergistically enhanced the phosphor-
ylation of Thr172 on myristoylated AMPKa, but not on nonmyris-
toylated AMPKa (Figure 6E). We also used AMPK immunopre-
cipitated from HEK293T cells and found again that AMP or
purified AXIN protein alone only moderately increased Thr172
phosphorylation level, whereas in the presence of both AMP
and AXIN, Thr172 phosphorylation was dramatically increased
(Figure S5D). AXIND507-731, defective in binding to AMPK or
LKB1, failed to promote Thr172 phosphorylation, indicating
that the binding to both LKB1 and AMPK is required for AXIN
to promote AMP-dependent phosphorylation of AMPK (Fig-
ure S5E). It has been reported that phosphatase PP2c is an
AXIN-interacting protein (Strovel et al., 2000) and involves in
the dephosphorylation of Thr172 on AMPK (Davies et al., 1995;
Hawley et al., 1996; Wang and Unger, 2005; Wu et al., 2007).
We thus also tested whether AXIN could regulate the dephos-
phorylation process of AMPK. As shown in Figure S5F, addition
of AXIN has no influence on PP2c-catalyzed dephosphorylationCellof AMPK. These results indicate that AXIN regulates AMPK activ-
ity mainly through promoting its phosphorylation by LKB1.
DISCUSSION
We have clearly demonstrated here that AXIN forms a complex
with AMPK and LKB1, which is initiated by AMP binding to the
g subunit of AMPK. Perhaps due to the lethality of its deficiency,
little was known about the physiological roles of AXIN in tissues
or at the organismal level. It is uncovered here that depletion of
AXIN in the liver, separately by two independent adenovirus-
based gene silencing vectors, engenders failure of AMPK activa-
tion, leading to dysregulation of the AMPK signaling axis. The
affected AMPK targets include ACC and SREBP-1C, which
converge to cause loss of lipid homeostasis as manifested by
exacerbated starvation-induced fatty liver in the mouse infected
by siAXIN-expressing adenoviruses (Figures 1A, 1B, and S1).
The essential role of AXIN in AMPK activation and lipid homeo-
stasis control can also be seen in cell-culture systems. Knock-
down of AXIN dampens AMPK activation in response to glucose
starvation or AICAR treatment in L02, HepG2, or MEF cells (Fig-
ures 2C–2E and S2D) and leads to accumulation of large lipid
droplets in L02 cells (Figures 2A and S2A) andMEF cells (Figures
2B, S2B, and S2C) cultured with supplemented oleic acid.
We have provided multiple lines of evidence to unravel the
mechanism for the role of AXIN in mediating AMP-triggered
AMPK activation by LKB1. First of all, depletion of AXIN abro-
gates colocalization of AMPK with LKB1 under starvation (Fig-
ure 3D), suggesting that AXIN plays a critical role in tethering
LKB1 to AMPK. We showed that AXIN directly interacts with
AMPK and LKB1 as determined by two-step coIP and by recon-
stitution using purified proteins (Figure S3G). The two critical reg-
ulators of LKB1, STRAD and MO25, are copresent in the AXIN-
LKB1-AMPK complex (Figure 3A), in an LKB1-dependent
manner (Figure S3B). Importantly, the interaction of AXIN with
AMPK depends on the presence of AMP (Figures 4A–4D). It is
conceivable that AMP binding, as an initial step in sensing a
low-energy state, increases the affinity of AMPK, likely by
causing changes in AMPK conformation (Chen et al., 2009), for
the scaffold protein AXIN that tethers the activating kinase
LKB1 to phosphorylate AMPK at Thr172 (Figure 6F). In earlier
studies, LKB1 was demonstrated to readily phosphorylate
AMPK in enzymatic assays (Hawley et al., 2003; Hong et al.,
2003; Shaw et al., 2004). Despite this, we were able to show
that LKB1 phosphorylation of AMPK is synergistically enhanced
in a reconstituted reaction that includes AXIN and AMP (Figures
6E and S5D). Consistently, mutations in the g subunit of AMPK
that fail to bind AMP cannot be stimulated by AXIN (Figure 4D).
These data emphasize the importance of AMP as a triggering
factor in initiating the activation of AMPK during starvation.
Furthermore, prior cotranslational modification by myristoyla-
tion, which has been shown to be a prerequisite step for AMPK
activation, is critical for AXIN to promote the activation of
AMPK triggered by AMP binding, determined in cells as well as
by in vitro reconstitution (Figures 5A–5F).
We found that ADP does not appear to play a role in promoting
the AXIN-based complex formation. Unlike AMP, ADP does not
promote interaction between AXIN and AMPK when added into
cell-free systems, nor does it promote LKB1-AMPK interactionMetabolism 18, 546–555, October 1, 2013 ª2013 Elsevier Inc. 551
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Figure 5. Myristoylation on AMPKb Is Required for AMP-Induced
AXIN-AMPK Interaction
(A) AMP only mildly increases the affinity of bacterially expressed un-
myristoylated AMPK for AXIN. Bacterially expressed AXIN was incubated with
HA-AMPK immunoprecipitated from HEK293T cells or His-AMPK purified
from E. coli. The mixtures were supplemented with 200 mM AMP and then
immunoprecipitated with antibody against AMPKa and subjected to immu-
noblotting with antibodies indicated.
(B) AMP-enhanced AMPK-AXIN interaction was blunted by overexpression of
AMPKb-G2A that cannot be myristoylated.
(C) Promotion of AXIN-AMPK interaction by AMP depends onmyristoylation of
AMPK. Purified AXIN and AMPK bacterially expressed with or without NMT1
were incubated with 200 mM AMP. The mixtures were immunoprecipitated
with antibody against AXIN and then subjected to immunoblotting with anti-
bodies indicated.
(D) AMP, but not ADP, enhances the interaction between AXIN and
myristoylated AMPK. Purified AXIN and myristoylated AMPK purified from
bacteria coexpressing NMT-1 were mixed with or without 200 mMAMP or ADP
as indicated. The mixtures were immunoprecipitated with antibody against
AXIN and then subjected to immunoblotting with antibodies indicated.
(E) AMP increases the binding affinity of AMPK for AXIN in a dose-dependent
manner. Purified AXIN and myristoylated AMPK were incubated with AMP in
the range between 0 and 500 mM. The mixtures were immunoprecipitated with
antibody against AXIN and then subjected to immunoblotting with antibodies
indicated.
(F) The region encompassing aa507–731of AXIN is essential for AMP-triggered
AXIN-AMPK association. AXIN or its deletion mutants were incubated with
myristoylated-AMPK with or without 200 mM AMP, followed by IP of AMPKa.
See also Figure S4.
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ing mild energy stress (Hardie et al., 2012b); when the ADP:ATP
ratio rises further under more severe stresses, the adenylate
kinase is displaced to convert ADP to AMP, giving rise to a sig-
nificant increase of AMP. It therefore stands to reason that the
AMP-driven AXIN-based activating loop may occur only during
severe energy stress, and that ADP displaces ATP in AMPK to
elicit an early response to energy shortage by sustaining
AMPK at its phosphorylated state, although it is possible that
ADP may also stimulate LKB1 phosphorylation of AMPK after
the formation of the complex (Oakhill et al., 2011). Our experi-
ments also conform to the finding that myristoylation is required
for AMPK activation. We showed that AMP fails to promote inter-
action of AXIN with unmyristoylated AMPK (Figure 5A), and
importantly that AMP or AXIN could not efficiently promote
LKB1 phosphorylation of nonmyristoylated AMPK, as assessed
by in vitro reconstitution experiments (Figure 6E).
In the regulation of the Wnt pathway, AXIN interacts with the
tumor suppressor adenomatous polyposis coli (APC), b-catenin,
casein kinases, and glycogen synthase kinase 3-b (GSK3-b),
serving as a platform for the degradation complex for b-catenin,
whose accumulation hasbeen linked to several cancer types (Sta-
mos andWeis, 2013). AXIN also assembles an activating complex
for p53 in response to DNA damage (Li et al., 2009). The AXIN-
GSK3 connection has also been shown to play a role in Wnt-
stimulated mTOR signaling and phosphorylates and inhibits the
tuberous sclerosis complex subunit 2 (TSC2) tumor suppressor,
which leads to deinhibition of mTOR (Inoki et al., 2006), pointing
to diverse roles of AXIN in regulating metabolic homeostasis. We
have shown that knockdown of AXIN leads to severely compro-
mised AMPK activation and ACC inhibition, which resulted in
severer fatty liver in mice under starvation and lipid accumulation
in cell-culture systems (Figures 1A–1C, 2A, and 2B). Whether or
not AXIN plays a general role in coordinating the regulation of
AMPK, mTOR, and lipid homeostasis remains to be further
explored. In addition, as AXIN is a key player of p53 signaling
that plays multiple functions in metabolism (Levine and Puzio-
Kuter, 2010; Li et al., 2009; Vousden, 2010), including regulation
of anabolic and catabolic pathways as well as its involvement in
AMPK signaling, it remains to be seen whether the AXIN-p53
axis also converges to regulate AMPK or form an intricate circuit
in the control of metabolic homeostasis. Moreover, it has recently
been shown that GSK3, which strongly interacts with AXIN, also
plays a part in regulation of AMPK activity (Suzuki et al., 2013). It
would be of interest to explore how the AXIN-GSK3 connection
would regulate AMPK signaling. Taken together, our current
work has provided the evidence of, and mechanistic insights
into, the initiating role of AMP in the activation of AMPK by
LKB1, an attribute of its ancestral role as a bona fide energy
sensor. We have also revealed that AXIN plays an essential role
inAMPKactivationand lipidhomeostasis.Moreover,wehavepro-
vided evidence to suggest that AMP and ADP may serve distinct
functions in response to different degrees of energy stress.EXPERIMENTAL PROCEDURES
Tail Vein Injection of Adenoviruses
Adenovirus was propagated in AD293 cells and purified by cesium
chloride density gradient ultracentrifugation. Adenoviruses (1 3 109c.
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Figure 6. AXIN Promotes Phosphorylation
of AMPK by LKB1
(A) AMP depends on AXIN to increase
association of AMPK with LKB1. AXIN, myristoy-
lated AMPK, and LKB1 complex were incubated
with or without AMP. The mixtures were then
immunoprecipitated with antibody against LKB1,
followed by immunoblotting with antibodies indi-
cated.
(B) AMP, but not ADP, enhances the interaction
between LKB1 and myristoylated AMPK. LKB1
complex (active, containing MO25 and STRAD),
myristoylated AMPK, and AXIN were incubated
with or without 200 mM AMP or ADP. The mixtures
were then immunoprecipitated with antibody
against LKB1, followed by immunoblotting with
antibodies indicated.
(C and D) Knockdown of AXIN in MEF cells,
by using siRNA expressing lentivirus, in MEF
cells diminished (C) AMP- or (D) AICAR-
enhanced interaction between AMPK and LKB1.
Cells were treated with 1 mM AICAR for 1 hr as
indicated.
(E) AXIN and AMP synergistically facilitate the
phosphorylation by LKB1 of AMPK that is
myristoylated. AMPK holoenzyme was ex-
pressed and purified from bacteria cotransformed
with or without NMT1. The conditions for kinase
reactions are described in the Experimental
Procedures.
(F) Simplified model demonstrating that AXIN
plays an essential role for AMPK activation by
orchestrating AMPK and LKB1. AMP exerts an
initiating role for the assembly of the AMPK acti-
vating complex, by increasing the affinity of AMPK
for AXIN that simultaneously binds LKB1. The re-
sulting complex brings LKB1 to the vicinity of
AMPK, promoting the phosphorylation of AMPK at
Thr172.
See also Figure S5.
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AXIN Is a Scaffold for AMPK Activation by LKB1plaque-forming units) were injected via tail veins of 3-month-old BALB/c
mice. Five days after injection, liver triglyceride contents were determined
using Labassay triglyceride reagent (290-63701, Wako Pure Chemical Indus-
tries, Ltd.).
Oil Red O Staining
Liver frozen sections were fixed in 10% formalin and then stained for 10 min
with Oil Red O. The red lipid droplets were visualized by microscopy.
Quantitative Real-Time PCR
Total RNA from liver was extracted with Trizol reagent. The cDNA was then
synthesized using M-MLV RTase system. The analyses were performed
using Step One Plus, the fast Real-Time PCR System from ABI (Applied
Biosystems).
Cell Culture
AMPKa1/2 DKOMEFs were kindly provided by Drs. Benoit Viollet and Keith R.
Laderoute. HEK293T and MEF cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. Human
liver L02 and HepG2 cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum.Cell Metabolism 18, 546–555Lentivirus Infection
Lentiviruses for infection of L02, HepG2, and MEF
cells were packaged in HEK293T cells usingLipofectamine 2000 transfection. Thirty hours after transfection, medium
was collected and added to the target cells.
Immunoprecipitation and Western Blotting
Cell lysis and IP were carried out as previously described (Rui et al., 2004), with
some modifications. Briefly, 50 mM NaCl was included in the lysis buffer
(20 mM Tris-HCl [pH 7.5], 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM
sodium orthovanadate, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluo-
ride). ADP or AMP (200 mM) was added into the lysis buffer before IP where
indicated. Cell lysates were incubated with respective antibodies overnight.
The overnight protein aggregates were removed by centrifugation, and protein
A/G beads were then added into the lysates and incubated for another 3 hr.
Levels of total proteins and the levels of phosphorylation of the corresponding
proteins were analyzed on separate gels.
Protein Production
Heterotrimeric AMPK (a1b1g1 and mutants indicated) was expressed in the
E. coli strain BL21 (DE3) as described previously (Neumann et al., 2003; Zhu
et al., 2011). To obtain myristoylated AMPK heterotrimer, pET21b-AMPK
was cotransformed with pET-28a-NMT1 and purified as described previously, October 1, 2013 ª2013 Elsevier Inc. 553
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AXIN Is a Scaffold for AMPK Activation by LKB1(Oakhill et al., 2010). The proteins were then purified with Nickel affinity gel
(catalog number P6611, Sigma) and followed by size exclusion chromatog-
raphy as described previously (Oakhill et al., 2010).
The pET32a-AXIN vector was transformed into the E. coli strain BL21 (DE3).
The transformed cells were induced with IPTG. After growing for 4 hr at 16C,
the cells were collected, homogenized, and sonicated. The supernatant was
collected and applied to ultracentrifugation at 150,0003 g for 30min, followed
by purification of expressed protein with Nickel affinity gel. The eluted protein
was then concentrated to about 3 mg/ml before further purification by gel
filtration.AMPKa-Thr172 Phosphorylation Assays
AMPK purified from E. coli (800 ng) was incubated with active LKB1/MO25/
STRAD complex (200 ng, at 32C, 15 min) in a kinase buffer (50 mM Tris-
HCl [pH 7.4], 50 mM NaCl, 2 mM MgCl2, 200 mM ATP) and 200 mM AMP
with or without AXIN (final reaction volume 50 ml).Statistical Analyses
ANOVA with Tukey’s post test was used to compare values among different
experimental groups using the SPSS Statistics 17.0 program. Values are pre-
sented as mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at http://dx.doi.org/10.1016/j.cmet.2013.09.005.ACKNOWLEDGMENTS
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